HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of “Hold” by Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has earned an average rating of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $20.8750.

Several brokerages recently commented on HCM. Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a report on Monday, January 19th. Finally, Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th.

HUTCHMED Stock Up 1.6%

Shares of HCM stock opened at $14.61 on Thursday. The business has a 50-day moving average of $14.31 and a 200 day moving average of $15.33. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $19.50.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its position in shares of HUTCHMED by 131.5% during the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock valued at $103,000 after buying an additional 4,378 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in HUTCHMED by 23.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after acquiring an additional 2,916 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the period. Bank of America Corp DE raised its position in shares of HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after acquiring an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.